Gain Therapeutics, Inc. (GANX) announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock. The public offering price for each set of two shares of common stock and an accompanying warrant to purchase one share of common stock is $3.11 per set of securities, resulting in an effective price of $1.55 per share and $0.01 per warrant.
Gain Therapeutics expects to receive aggregate gross proceeds from the offering of approximately $7.0 million, with the offering anticipated to close on or about July 17, 2025.
The company intends to use the net proceeds to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease and for general corporate purposes.
